300485 Beijing Science Sun Pharmaceutical
- 6.27
- -0.12-1.88%
Beijing Science Sun Pharmaceutical News
Beijing Science Sun Pharmaceutical (300485.SZ): The main products are biopharmaceuticals, involving three major fields of medication for cardiovascular diseases, immune diseases (anti-tumor) and nervous system diseases.
Beijing Science Sun Pharmaceutical (300485.SZ) stated on the investor interaction platform that the company's leading products are biopharmaceutical products involving three major therapeutic areas: cardiovascular and cerebrovascular diseases, immunological diseases (anti-tumor) and neurological diseases. The company is the original drafting unit of national drug standards for five varieties of products, including fibrinolytic enzyme, fibrinolytic enzyme injection, injection fibrinolytic enzyme, thinsetide injection, and deoxyribonucleoside sodium injection; fibrinolytic enzyme injection, thinsetide injection and 100mg injection of thymopeptide are the first drugs to be produced in China; monosialotetrahexosylganglioside sodium injection.
Saisheng Pharmaceutical (300485.SZ): The company is not involved in the vaccine business
Gelonghui, May 27 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that the company's shareholding company Luzhu Biotech is a company whose main research direction is human vaccines and therapeutic bifunctional antibody drugs. Please check its official and statutory disclosure information websites for relevant information. The company is not involved in the vaccine business.
Saisheng Pharmaceutical (300485.SZ) plans to pay 0.22 yuan for 10 shares to be deducted from interest on May 29
Saisheng Pharmaceutical (300485.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Saisheng Pharmaceutical (300485.SZ): It has genetic engineering and biological extraction technology, and can be applied to synthetic biology. Currently, the company is not involved in this business
Gelonghui, May 8 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that the company has genetic engineering and biological extraction technology, which can be applied to synthetic biology. Currently, the company is not involved in this business. Among the investment projects initiated by the company, 3 companies involved synthetic biology: Shanxi Kaisheng Biotechnology Co., Ltd., Chengdu Yatu Biotechnology Co., Ltd., and Like Times (Wuhan) Biotechnology Co., Ltd.
Saisheng Pharmaceutical (300485.SZ): Net loss of 190 million yuan in the first quarter turned into a year-on-year loss
On April 25, Gelonghui | Saisheng Pharmaceutical (300485.SZ) released its first quarter report. Operating revenue was 110 million yuan, down 17.46% year on year, net loss was 190 million yuan, turning loss year on year. After deducting non-net profit of 15.1578 million yuan, up 383.81% year on year, and basic earnings per share -0.3957 yuan.
Saisheng Pharmaceutical (300485.SZ): As of April 10, 2024, the number of shareholders of the company was 31,397
Gelonghui, April 12 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 31,397.
Saisheng Pharmaceutical (300485.SZ): Net profit for 2023 decreased by 49.73% to 103 million yuan, plans to distribute 10 to 0.22 yuan
Gelonghui, April 9 | Saisheng Pharmaceutical (300485.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 477 million yuan, a year-on-year decrease of 35.12%; net profit attributable to shareholders of listed companies was 103 million yuan, a year-on-year decrease of 49.73%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses; basic earnings per share of 0.21 yuan; it plans to distribute a cash dividend of 0.22 yuan (tax included) for every 10 shares to all shareholders.
Saisheng Pharmaceutical (300485.SZ): As of March 20, 2024, the number of shareholders of the company was 31,736
Gelonghui March 25 | Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that as of March 20, 2024, the number of shareholders of the company was 31,736.
Saisheng Pharmaceutical (300485.SZ): Centralized procurement of selected drugs from sodium deoxynucleotide injections and arginine hydrochloride injections
Gelonghui, March 20 | Saisheng Pharmaceutical (300485.SZ) announced that the company participated in the Beijing-Tianjin-Hebei “3+N” Alliance Drug Centralized Procurement and Centralized Volume Procurement Work carried out by Guangzhou Trading Group Co., Ltd., according to the “Notice on Accomplishing the Implementation of the Ninth Batch of National Organization Collection and the Beijing-Tianjin-Hebei “3+N” Alliance Drug Centralized Procurement Results” issued by the Tianjin Municipal Medical Security Administration (Tianjin Pharmaceutical Collection [2024] No. 3) and the “Guangzhou Trading Group Co., Ltd. Announces Emergency and Rescue Drug Alliance” issued by the Guangzhou Public Resources Exchange Center Selection/preparation in centralized volume procurement
Saisheng Pharmaceutical (300485.SZ): Change of pharmaceutical production license for subsidiary Junyuan Pharmaceutical
Gelonghui, Feb. 26 | Saisheng Pharmaceutical (300485.SZ) announced that its subsidiary Shenyang Junyuan Pharmaceutical Co., Ltd. (“Junyuan Pharmaceutical”) recently obtained a “Pharmaceutical Production License” issued by the Liaoning Provincial Drug Administration. The matters involved in this change are: it was agreed that the company would change the production site of Strong Kidney Tablets (Sinopharm standard Z21020715, each tablet weighs 0.3 g) from No. 6, Lane 103, Lingyun Street, Dongling District, Shenyang City to Building 9 and 22, No. 603, Maizitun, Hunnan District, Shenyang City. Other details remained unchanged.
Saisheng Pharmaceutical (300485.SZ): Projects under development are class 1 new drugs such as antiangitide, angiogenic inhibitor peptides, etc.
Gelonghui, Feb. 21丨Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that the company is a national high-tech biomedical enterprise covering the fields of high-end preparations, biopharmaceuticals, modern traditional Chinese medicines, APIs, medical devices, biological breeding, etc. The company is rooted in the pharmaceutical industry and is based on innovation and research and development. Currently, the company's research projects include antianjil peptides, angiogenic peptides, etc. as class 1 new drugs.
Saisheng Pharmaceutical (300485.SZ): 2023 net profit pre-reduced by 45%-60%
Gelonghui, January 29丨Saisheng Pharmaceutical (300485.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 8,1894 million yuan - 112,6043 million yuan, down 45%-60% from the same period of the previous year; net profit loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 42,616 million yuan - 52,533,600 yuan, profit of 334,400 yuan for the same period last year; basic earnings per share were 0.15 yuan/share - 0.25 yuan/share. The company expects net profit attributable to shareholders of listed companies in 2023
Saisheng Pharmaceutical (300485.SZ): Strong Kidney Granules are a product of the subsidiary Junyuan Pharmaceutical. Currently, they do not account for much of the company's overall revenue
Gelonghui, January 22丨An investor asked Saisheng Pharmaceutical (300485.SZ) on the investor interactive platform, “Does the company's strong kidney granules account for 1% of the company's operating revenue in the market?” The company replied that Qiangkidney Granule is a product of its subsidiary Junyuan Pharmaceutical. The product has completed a change in production site and can be marketed for sale. Sales work is gradually being carried out, and currently it does not account for much of the company's overall revenue.
Saisheng Pharmaceutical (300485.SZ): Currently, research projects involving cardiovascular and cardiovascular systems include GGE3, JTYM, etc., and are in the pre-clinical research stage
Glonghui, December 13|Some investors asked Saisheng Pharmaceutical (300485.SZ) on the investor interactive platform, “There are many patients with respiratory infections and influenza viruses every winter. Has the company increased production of anti-virus drugs and anti-allergic antidotes? Is there room for the company to improve cardiovascular, diabetes and other products in the future?” The company replied that the company will arrange production plans reasonably according to the order situation. On the basis of the original product structure, the company combined with the company's existing resource conditions to carry out in-depth research on polypeptide biomedicine, new biomaterials, and diagnosis, treatment and management of chronic diseases, making full use of state support for biomedical production
Saisheng Pharmaceutical (300485.SZ): The company passed the national high-tech enterprise re-certification
Gelonghui November 30丨Saisheng Pharmaceutical (300485.SZ) announced that it recently received the “High-tech Enterprise Certificate” jointly issued by the Beijing Municipal Science and Technology Commission, the Beijing Municipal Finance Bureau, and the Beijing Municipal Taxation Bureau of the State Administration of Taxation. The certification period is October 26, 2023, and the validity period is three years. This is a re-certification carried out after the company's original high-tech enterprise certificate expires.
Saisheng Pharmaceutical (300485.SZ): Injecting thymotide products can prevent upper respiratory infections
Gelonghui November 27丨Saisheng Pharmaceutical (300485.SZ) said on the investor interactive platform that patients often showed upper respiratory symptoms after syncytial virus infection. Injecting thymopeptide in the company's products can prevent upper respiratory infections. Junyuan Pharmaceutical and Cyerbio, a holding subsidiary of the company, have products suitable for upper respiratory infections, and drug use must be in accordance with medical advice.
Saisheng Pharmaceutical (300485.SZ): As of November 10, 2023, the number of shareholders in the company is 32766
Gelonghui November 17丨Saisheng Pharmaceutical (300485.SZ) stated on the investor interactive platform that as of November 10, 2023, the number of shareholders in the company was 32766.
Saisheng Pharmaceutical (300485.SZ) released results for the first three quarters, with net profit of 197 million yuan, a decrease of 22.21%
Saisheng Pharmaceutical (300485.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 3...
Saisheng Pharmaceutical (300485.SZ): Withdrawal of registration application for injectable napalimostat mesylate
Glonghui, October 20: Saisheng Pharmaceutical (300485.SZ) announced that in accordance with the adjustment of the corporate application strategy, Beijing Saisheng Pharmaceutical Co., Ltd. submitted an “Application for Withdrawing the Registration Application for Injectable Naemostat Mesylate” to the Drug Evaluation Center of the State Drug Administration. Recently, Saisheng Pharmaceutical received the “Notice of Termination of Drug Registration Application” from the State Drug Administration agreeing to withdraw the registration application. Injectable namostat mesylate is used to improve acute symptoms of pancreatitis; treat diffuse intravascular coagulation syndrome (DIC); and prevent blood circulation outside the body in patients with hemorrhagic lesions or bleeding tendencies
Saisheng Pharmaceutical (300485.SZ): The subsidiary Junyuan Pharmaceutical has an approval number for metformin hydrochloride tablets, which are currently not produced
Glonghui, Oct. 16丨An investor asked Saisheng Pharmaceutical (300485.SZ) on the investor interactive platform, “Does your company manufacture and sell metformin hydrochloride tablets? What are the main benefits of this product?” The company replied that its subsidiary, Junyuan Pharmaceutical, has the approval number for metformin hydrochloride tablets and has not yet produced them. Main effects of this product: It is used for type II diabetics who are not satisfied with diet control alone, especially those who are obese and have hyperinsulinemia. Using this drug not only has a hypoglycemic effect, but may also have the effect of reducing weight and hyperinsulinemia. It works for patients with poor efficacy with certain sulfonylureas, such as
Analysis
Price Target
No Data
